What is Zacks Research’s Estimate for PRE Q1 Earnings?
by Kim Johansen · The Markets DailyPrenetics Global Limited (NASDAQ:PRE – Free Report) – Stock analysts at Zacks Research issued their Q1 2026 earnings estimates for Prenetics Global in a research report issued to clients and investors on Wednesday, April 8th. Zacks Research analyst B. Sorensen forecasts that the company will post earnings of ($0.73) per share for the quarter. The consensus estimate for Prenetics Global’s current full-year earnings is ($3.30) per share. Zacks Research also issued estimates for Prenetics Global’s Q2 2026 earnings at ($0.67) EPS, Q3 2026 earnings at ($0.59) EPS, Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.49) EPS, Q1 2027 earnings at ($0.32) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at $0.22 EPS, Q4 2027 earnings at $0.52 EPS and FY2027 earnings at $0.37 EPS.
Prenetics Global (NASDAQ:PRE – Get Free Report) last issued its earnings results on Wednesday, February 18th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.22. The business had revenue of $36.60 million during the quarter, compared to analysts’ expectations of $36.15 million. Prenetics Global had a negative net margin of 61.33% and a negative return on equity of 19.07%.
Several other research analysts have also recently issued reports on PRE. Wall Street Zen cut shares of Prenetics Global from a “buy” rating to a “hold” rating in a report on Monday, February 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a report on Thursday, January 22nd. Lake Street Capital initiated coverage on shares of Prenetics Global in a report on Monday, March 16th. They issued a “buy” rating and a $29.00 target price for the company. Finally, Roth Mkm initiated coverage on shares of Prenetics Global in a report on Wednesday, February 11th. They issued a “buy” rating and a $36.00 target price for the company. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Prenetics Global has a consensus rating of “Moderate Buy” and an average price target of $32.33.
Get Our Latest Stock Analysis on PRE
Prenetics Global Stock Performance
Shares of Prenetics Global stock opened at $17.47 on Friday. The stock has a market capitalization of $294.02 million, a PE ratio of -4.35 and a beta of 0.27. Prenetics Global has a 52-week low of $3.09 and a 52-week high of $23.63. The company has a 50-day simple moving average of $19.42 and a two-hundred day simple moving average of $16.52.
Prenetics Global announced that its Board of Directors has initiated a stock repurchase plan on Friday, March 6th that allows the company to buyback $40.00 million in shares. This buyback authorization allows the company to purchase up to 15.8% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its stock is undervalued.
Institutional Trading of Prenetics Global
Large investors have recently added to or reduced their stakes in the business. Aberdeen Group plc bought a new stake in Prenetics Global during the third quarter valued at approximately $979,000. OMERS ADMINISTRATION Corp bought a new stake in Prenetics Global during the fourth quarter valued at approximately $307,000. Hudson Bay Capital Management LP bought a new stake in Prenetics Global during the fourth quarter valued at approximately $296,000. Jump Financial LLC bought a new stake in Prenetics Global during the fourth quarter valued at approximately $268,000. Finally, Boothbay Fund Management LLC bought a new stake in Prenetics Global during the fourth quarter valued at approximately $241,000. 25.01% of the stock is currently owned by institutional investors.
About Prenetics Global
Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.
Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.